Latest Europe News

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

Unibail-Rodamco-Westfield delivered robust FY-2024 results with a 7% rise in like-for-like EBITDA and adjusted recurring EPS surpassing guidance, supported by strong retail and convention business performance. The company also announced a 40% increase in its proposed dividend, reflecting confidence in its financial health and strategic asset management.

Krakatoa Resources has provided a detailed update on its Zopkhito Antimony-Gold Project in Georgia, revealing significant exploration data and a strategic plan to advance towards JORC-compliant resources.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.

Latitude 66 Limited is set to commence a pioneering Reverse Circulation (RC) drilling trial at its KSB North Project in Finland, aiming to unlock high-grade gold and cobalt mineralisation at the K6E and K6W Prospects. This move could significantly enhance exploration efficiency and reduce costs across the project.

Orora reports a 24.6% rise in underlying EBIT to $120.8 million for H1 FY25, driven by the Saverglass acquisition and portfolio simplification, while navigating operational challenges and market headwinds.

Magnum Mining & Exploration is recalibrating its supply chain strategy in response to new U.S. tariffs on steel and aluminium, engaging with Chinese partners and advancing its Buena Vista iron project.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Amotiv Limited reported a modest 2.3% revenue increase in the first half of FY25, underpinned by acquisitions and strategic initiatives despite organic revenue softness and margin pressures. The company anticipates a stronger second half driven by new business wins and pricing actions.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

CSL Limited posted a robust half-year performance with NPATA rising 5% at constant currency, driven by strong growth in CSL Behring and CSL Vifor despite challenges in its influenza vaccine segment. The company reaffirmed its FY25 guidance, anticipating double-digit earnings growth.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.